Clearside Biomedical Submits New Drug Application for XIPERE for the Treatment of Macular Edema Associated with Uveitis
pharmaceutical investing Clearside Biomedical Announces Fourth Quarter 2017 Financial Results and Provides Corporate Update
pharmaceutical investing Clearside Biomedical Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of CLS-TA
pharmaceutical investing Clearside Biomedical Announces First Patient Randomized in Phase 3 Clinical Trial of Zuprata™ Used Together With Eylea in Subjects With Retinal Vein Occlusion
Surface Metals to Present at Fastmarkets Global Lithium, Battery & Critical Materials Conference in Las Vegas, Nevada
Nine Mile Metals Announces Completion of DDH WD-26-02,Intersecting 234.15 Meters of Visual Mineralization and Discovers a New Copper Rich VMS Horizon at the Wedge Mine
